IRIS
GENTILE, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.581
NA - Nord America 1.338
EU - Europa 1.028
SA - Sud America 220
AF - Africa 27
OC - Oceania 2
Totale 4.196
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.315
SG - Singapore 952
IT - Italia 575
CN - Cina 508
BR - Brasile 199
FI - Finlandia 123
DE - Germania 106
NL - Olanda 78
HK - Hong Kong 57
AT - Austria 47
GB - Regno Unito 17
KR - Corea 15
RU - Federazione Russa 15
FR - Francia 13
CZ - Repubblica Ceca 11
UA - Ucraina 11
CA - Canada 10
ZA - Sudafrica 8
AR - Argentina 7
BD - Bangladesh 7
SN - Senegal 7
IN - India 5
MX - Messico 5
PA - Panama 5
GR - Grecia 4
MA - Marocco 4
EC - Ecuador 3
IE - Irlanda 3
IQ - Iraq 3
JP - Giappone 3
NO - Norvegia 3
PH - Filippine 3
PK - Pakistan 3
TR - Turchia 3
VE - Venezuela 3
AZ - Azerbaigian 2
CO - Colombia 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PL - Polonia 2
PT - Portogallo 2
RO - Romania 2
SA - Arabia Saudita 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
BE - Belgio 1
BG - Bulgaria 1
BO - Bolivia 1
CH - Svizzera 1
CL - Cile 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
ES - Italia 1
HU - Ungheria 1
KE - Kenya 1
KH - Cambogia 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PY - Paraguay 1
SE - Svezia 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 4.196
Salva come PNG Salva come JPEG
Città #
Boardman 642
Florence 315
Singapore 283
Shanghai 209
Helsinki 110
Ashburn 72
Ogden 68
Hong Kong 55
Sesto Fiorentino 47
Noto 45
Amsterdam 41
Munich 40
Vienna 35
Los Angeles 30
Guangzhou 28
Wuhan 27
New York 23
Chandler 19
Washington 19
Rome 18
São Paulo 18
Beijing 17
Santa Clara 15
Seoul 15
Naaldwijk 14
Falkenstein 13
Frankfurt am Main 13
Lappeenranta 12
Milan 10
Rende 10
Jinhua 9
Seattle 9
Brasília 8
Rio de Janeiro 8
Catania 7
Dakar 7
Yiwu 7
Wuxi 6
Bari 5
Belo Horizonte 5
Cosenza 5
Jiaxing 5
Kilburn 5
Nuremberg 5
Zibo 5
Athens 4
Cabo Frio 4
Chicago 4
London 4
Montreal 4
Naples 4
Recife 4
São Luís 4
Bologna 3
Brooklyn 3
Council Bluffs 3
Dalian 3
Dhaka 3
Dublin 3
Fortaleza 3
Genoa 3
Hangzhou 3
Hortolândia 3
Lawrence 3
Mexico City 3
Oslo 3
Palmi 3
Paris 3
Presidente Prudente 3
Roxbury 3
Salvador 3
San Francisco 3
Sassari 3
São José dos Campos 3
The Dalles 3
Tokyo 3
Toronto 3
Addis Ababa 2
Ann Arbor 2
Antalya 2
Aracaju 2
Astana 2
Baghdad 2
Baku 2
Borgomanero 2
Bratislava 2
Bucharest 2
Caxias do Sul 2
Contagem 2
Cuiabá 2
Curitiba 2
Denver 2
Elk Grove Village 2
Enfield 2
Feira de Santana 2
Forlì 2
Gravataí 2
Gualdo Tadino 2
Guarulhos 2
Heze 2
Totale 2.509
Salva come PNG Salva come JPEG
Nome #
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 86
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 51
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 45
A novel phage display based platform for exosome diversity characterization 44
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 41
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 41
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 40
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 37
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 37
Momelotinib in myelofibrosis 37
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 36
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 35
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 34
Selinexor in multiple myeloma 34
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 34
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 33
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 33
Elotuzumab in multiple myeloma 33
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 32
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 32
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 31
Iron chelation therapy 31
Teclistamab-cqyv in multiple myeloma 31
Cerebral pheohyphomycosis due to curvularia species 30
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 30
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 30
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 30
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 29
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 29
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 29
Belantamab mafodotin in multiple myeloma 29
Myelodysplastic syndromes with ring sideroblasts 28
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 28
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 28
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 27
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 27
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 27
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients 27
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 27
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 27
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 27
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 26
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 26
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 26
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 25
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 25
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 25
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 24
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 24
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 24
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 24
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients 24
The use of ibrutinib before and after allogeneic stem cell transplantation 23
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 23
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 23
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. 23
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 23
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 23
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial 22
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 22
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 22
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 22
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity 22
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 21
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma 21
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 21
Acalabrutinib in chronic lymphocytic leukemia 21
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 21
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 21
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications 21
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 20
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy 20
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 20
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 20
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 20
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 20
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 20
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 20
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. 20
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 20
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 19
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 19
Glasdegib for the treatment of acute myeloid leukemia 19
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 19
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 19
An old drug with a new future: bendamustine in multiple myeloma 19
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. 19
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey 18
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. 18
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 17
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients 17
Ivosidenib in acute myeloid leukemia 17
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 17
An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. 17
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 17
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI) 17
Editorial: Lymphoid cells and tumor microenvironment: a functional crosstalk 17
Zanubrutinib for the treatment of chronic lymphocytic leukemia 17
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment 16
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 16
Totale 2.619
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.269
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 4 2 0 0 0 1 0 1 0 0
2021/202224 0 2 0 0 2 0 0 6 1 1 5 7
2022/2023442 6 5 3 11 8 5 279 22 19 20 50 14
2023/20241.536 35 36 245 194 97 153 80 48 120 50 67 411
2024/20252.537 179 611 112 151 165 137 88 170 721 203 0 0
Totale 4.547